However, studies on endogenous LEDGF/p75 protein interactions in clinically relevant cancer cellular models have been more challenging due to the relatively low expression of some IBD interactome proteins in many established cell lines, as well as the limited availability of antibodies that can efficiently co-IP endogenous LEDGF/p75 with its interacting partners. This evidence concerns the gene PSIP1 and cancer.